Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for STAT6 inhibitor ...

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Also Announces Extension of IR Program VANCOUVER, BC / ACCESS Newswire / May 1, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") is ...

Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy.

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with ...

Factor XI inhibition was potentially the Goldilocks anticoagulant target with the promise of a reduction in thrombotic risk without a significant increase in bleeding. The early phase 2 data were ...

Please provide your email address to receive an email when new articles are posted on . Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at ...

Responses observed in patients with and without previous exposure to other KRAS G12C inhib ...